ChromoCure Heralds Publication of "Polyploidization and Cancer" as Paradigm Shift in Cancer Diagnosis and Therapy: Company Expec
2010年3月18日 - 10:00PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) heralds the March 15, 2010
publication of "Polyploidization and Cancer." This publication is
viewed as a major turning point and paradigm shift in the
diagnosis, therapy and cure of cancer. The Company views this as
significant support of its long held theory of cancer and its
Chromosomal Scanner detection technology. Published as part of
Advances in Experimental Medicine and Biology Series: Vol. 676
(ISBN: 978-1-4419-6198-3) and edited by Randy Y.C. Poon, this book
brings together leaders of the field to overview subjects relating
to Polyploidization, aneuploidy and cancer.
This authoritative collection of research further corroborates
recent studies by Mayo Clinic and others that have conclusively and
irrefutably demonstrated aneuploidy as a more accurate predictor of
cancer than cytological/histological analysis or genetic
marker-based diagnostics that are the only other methods in
existence today. ChromoCure designs its technology around the
chromosomal theory of cancer.
The Company's proprietary Chromosomal Scanner systems have
proven accurate and efficient in the measurement of the unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has been proven
to have an effective accuracy of 100% for all cancers at all
stages. This is superior to other detection approaches presently
employed by pathologists, including biomarker detection, in every
measurable way. ChromoCure's systems measure aneuploidy as the sole
means of detecting cancer presence and measuring cancer
progression. The system has a 100% effective accuracy rate, as
verified in the recently published collaborative clinical testing
with a major cancer clinic.
The company's technology and related research opens the way for
non-invasive and non-toxic solutions to cancer therapeutics and
disease eradication. Given the significant change in scientific
views currently underway, the company has aligned itself to focus
its leadership status to therapeutics research. These new
initiatives add to the Company's existing scanner technologies
which include proprietary designs, processes, and algorithms
centered on chromosomal imbalance. The Company believes its
technologies provide the foundation for significant advantages in
delivering important results in diagnosis, therapy and cure.
The Company invites industry and scientific collaboration
through its "Project Boveri: Find the Cure" initiative.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary CS200 Chromosomal Scanner has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's detection technology has an effective accuracy of 100%
for all cancers at all stages. The Company believes its technology
will become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548 1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Chromocure Inc (CE) (その他OTC): 0 recent articles
その他のChromoCure, Inc.ニュース記事